1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646-674.
2. Balkwill FR, Capasso M, Hagemann T. The tumor microenvironment
at a glance. J Cell Sci. 2012;125:5591-5596.
3. Alkasalias T, Moyano-Galceran L, Arsenian-Henriksson M, Lehti K.
Fibroblasts in the tumor microenvironment: shield or spear? Int J
Mol Sci. 2018;19:1532.
4. Wang Z, Yang Q, Tan Y, et al. Cancer-associated fibroblasts suppress cancer development: the other side of the coin. Front Cell Dev
Biol. 2021;9: 613534.
5. Chakraborty S, Sinha S, Sengupta A. Emerging trends in chromatin
remodeler plasticity in mesenchymal stromal cell function. FASEB J.
2021;35:e21234.
6. Rinn JL, Bondre C, Gladstone HB, Brown PO, Chang HY. Anatomic
demarcation by positional variation in fibroblast gene expression
programs. PLoS Genet. 2006;2:e119.
7. Adekoya TO, Richardson RM. Cytokines and chemokines as mediators of prostate cancer metastasis. Int J Mol Sci. 2020;21:4449.
8. Dominiak A, Chełstowska B, Olejarz W, Nowicka G. Communication
in the cancer microenvironment as a target for therapeutic interventions. Cancers (Basel). 2020;12:1232.
9. Ahmat Amin MKB, Shimizu A, Zankov DP, et al. Epithelial membrane protein 1 promotes tumor metastasis by enhancing cell migration via copine-III and Rac1. Oncogene. 2018;37:5416-5434.
10. Rahman NIA, Sato A, Tsevelnorov K, et al. Stomatin-mediated inhibition of the Akt Signaling axis suppresses tumor growth. Cancer
Res. 2021;81:2318-2331.
11. Wilson HL, Wilson SA, Surprenant A, North RA. Epithelial membrane proteins induce membrane blebbing and interact with the
P2X7 receptor C terminus. J Biol Chem. 2002;277:34017-3 4023.
12. Li ZY, Xiong SH, Hu M, Zhang CS. Epithelial membrane protein
1 inhibits human spinal chondrocyte differentiation. Anat Rec
(Hoboken). 2011;294:1015-1024.
13. Ashki N, Gordon L, Wadehra M. Review of the GAS3 family of proteins and their relevance to cancer. Crit Rev Oncog. 2015;20:435-4 47.
14. Ahmat Amin MKB, Shimizu A, Ogita H. The pivotal roles of the epithelial membrane protein family in cancer invasiveness and metastasis. Cancers (Basel). 2019;11:1620.
15. Heinrich C, Keller C, Boulay A, et al. Copine-III interacts with ErbB2
and promotes tumor cell migration. Oncogene. 2010;29:1598-1610.
16. Shimazaki K, Lepin EJ, Wei B, et al. Diabodies targeting epithelial
membrane protein 2 reduce tumorigenicity of human endometrial
cancer cell lines. Clin Cancer Res. 2008;14:7367-7377.
17. Sun GG, Wang YD, Cui DW, Cheng YJ, Hu WN. EMP1 regulates
caspase-9 and VEGFC expression and suppresses prostate cancer
cell proliferation and invasion. Tumour Biol. 2014;35:3455-3 462.
18. Echevarria MI, Awasthi S, Cheng CH, et al. African American specific gene panel predictive of poor prostate cancer outcome. J Urol.
2019;202:247-255.
19. Turashvili G, Bouchal J, Baumforth K, et al. Novel markers for differentiation of lobular and ductal invasive breast carcinomas
by laser microdissection and microarray analysis. BMC Cancer.
2007;7:55.
20. Arpino G, Bardou VJ, Clark GM, Elledge RM. Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome.
Breast Cancer Res. 2004;6:R149-R156.
21. Sun GG, Wang YD, Lu YF, Hu WN. EMP1, a member of a new
family of antiproliferative genes in breast carcinoma. Tumour Biol.
2014;35:3347-3354.
22. Miao L, Jiang Z, Wang J, et al. Epithelial membrane protein 1 promotes glioblastoma progression through the PI3K/AKT/mTOR signaling pathway. Oncol Rep. 2019;42:605-614.
23. Lapatsina L, Brand J, Poole K, Daumke O, Lewin GR. Stomatin-
domain proteins. Eur J Cell Biol. 2012;91:240-245.
24. Browman DT, Hoegg MB, Robbins SM. The SPFH domain-
containing proteins: more than lipid raft markers. Trends Cell Biol.
2007;17:394-4 02.
25. Wang D, Tabti R, Elderwish S, et al. SFPH proteins as therapeutic targets for a myriad of diseases. Bioorg Med Chem Lett.
2020;30:127600.
26. Stewart GW. Stomatin. Int J Biochem Cell Biol. 1997;29:271-274.
27. Zhu Y, Paszty C, Turetsky T, et al. Stomatocytosis is absent in “stomatin”-
deficient murine red blood cells. Blood.
1999;93:2404-2410.
28. Genetet S, Desrames A, Chouali Y, Ripoche P, Lopez C, Mouro-
Chanteloup I. Stomatin modulates the activity of the Anion
Exchanger 1 (AE1, SLC4A1). Sci Rep. 2017;7:46170.
29. Rungaldier S, Oberwagner W, Salzer U, Csaszar E, Prohaska R.
Stomatin interacts with GLUT1/SLC2A1, band 3/SLC4A1, and
aquaporin-1 in human erythrocyte membrane domains. Biochim
Biophys Acta. 2013;1828:956-966.
3 0. Brand J, Smith ES, Schwefel D, et al. A stomatin dimer modulates the
activity of acid-sensing ion channels. EMBO J. 2012;31:3635-3646.
31. Chen JC, Cai HY, Wang Y, et al. Up-regulation of stomatin expression by hypoxia and glucocorticoid stabilizes membrane-associated
actin in alveolar epithelial cells. J Cell Mol Med. 2013;17:863-872.
32. Snyers L, Thinès-Sempoux D, Prohaska R. Colocalization of stomatin (band 7.2b) and actin microfilaments in UAC epithelial cells. Eur J
Cell Biol. 1997;73:281-285.
33. Lee JH, Hsieh CF, Liu HW, et al. Lipid raft-associated stomatin enhances cell fusion. FASEB J. 2017;31:47-59.
3 4. Porta C, Paglino C, Mosca A. Targeting PI3K/Akt/mTOR signaling in
cancer. Front Oncol. 2014;4:64.
35. Fujita N, Sato S, Ishida A, Tsuruo T. Involvement of Hsp90 in signaling and stability of 3-phosphoinositide-dependent kinase-1. J Biol
Chem. 2002;277:10346-10353.
36. Chen CY, Yang CY, Chen YC, Shih CW, Lo SS, Lin CH. Decreased
expression of stomatin predicts poor prognosis in HER2-positive
breast cancer. BMC Cancer. 2016;16:697.
37. An H, Ma X, Liu M, et al. Stomatin plays a suppressor role in non-small
cell lung cancer metastasis. Chin J Cancer Res. 2019;31:930-944.
38. Zhang L, Ding F, Cao W, et al. Stomatin-like protein 2 is overexpressed in cancer and involved in regulating cell growth and cell adhesion in human esophageal squamous cell carcinoma. Clin Cancer
Res. 2006;12:1639-1646.
39. Yang CT, Li JM, Li LF, Ko YS, Chen JT. Stomatin-like protein 2 regulates survivin expression in non-small cell lung cancer cells through
β-c atenin signaling pathway. Cell Death Dis. 2018;9:425.
4 0. Zhou C, Li Y, Wang G, et al. Enhanced SLP-2 promotes invasion
and metastasis by regulating Wnt/β-
c atenin signal pathway in
colorectal cancer and predicts poor prognosis. Pathol Res Pract.
2019;215:57-67.
41. Sun F, Ding W, He JH, Wang XJ, Ma ZB, Li YF. Stomatin-like protein
2 is overexpressed in epithelial ovarian cancer and predicts poor
patient survival. BMC Cancer. 2015;15:746.
42. Yang J, Li B, He QY. Significance of prohibitin domain family in tumorigenesis and its implication in cancer diagnosis and treatment.
Cell Death Dis. 2018;9:580.
43. Wang S, Nath N, Adlam M, Chellappan S. Prohibitin, a potential
tumor suppressor, interacts with RB and regulates E2F function.
Oncogene. 1999;18:3501-3510.
8 4 4. Rajalingam K, Wunder C, Brinkmann V, et al. Prohibitin is required
for Ras-induced Raf-MEK-ERK activation and epithelial cell migration. Nat Cell Biol. 2005;7:837-8 43.
45. Gauthier-Rouvière C, Bodin S, Comunale F, Planchon D.
Flotillin membrane domains in cancer. Cancer Metastasis Rev.
2020;39:361-374.
46. Snyers L, Content J. Induction of metallothionein and stomatin by
interleukin-6 and glucocorticoids in a human amniotic cell line. Eur J
Biochem. 1994;223:411-418.
47. Cain DW, Cidlowski JA. Immune regulation by glucocorticoids. Nat
Rev Immunol. 2017;17:233-247.
4 8. Cook AM, McDonnell AM, Lake RA, Nowak AK. Dexamethasone
co-
m edication in cancer patients undergoing chemotherapy
causes substantial immunomodulatory effects with implications for chemo-
immunotherapy strategies. Oncoimmunology.
2016;5:e1066062.
49. Giehl K, Menke A. Microenvironmental regulation of E-c adherin-
mediated adherens junctions. Front Biosci. 2008;13:3975-3985.
50. Niessen CM, Gottardi CJ. Molecular components of the adherens
junction. Biochim Biophys Acta. 2008;1778:562-571.
51. Takai Y, Miyoshi J, Ikeda W, Ogita H. Nectins and nectin-like molecules: roles in contact inhibition of cell movement and proliferation.
Nat Rev Mol Cell Biol. 2008;9:603-615.
52. Labernadie A, Kato T, Brugués A, et al. A mechanically active heterotypic E-c adherin/N-c adherin adhesion enables fibroblasts to
drive cancer cell invasion. Nat Cell Biol. 2017;19:224-237.
53. Loh CY, Chai JY, Tang TF, et al. The E-C adherin and N-C adherin
switch in epithelial-to-mesenchymal transition: signaling, therapeutic implications, and challenges. Cells. 2019;8:1118.
54. Hazan RB, Qiao R, Keren R, Badano I, Suyama K. Cadherin switch in
tumor progression. Ann N Y Acad Sci. 2004;1014:155-163.
55. McAndrews KM, Yi J, McGrail DJ, Dawson MR. Enhanced adhesion
of stromal cells to invasive cancer cells regulated by Cadherin 11.
ACS Chem Biol. 2015;10:1932-1938.
56. Apostolopoulou M, Ligon L. Cadherin-23 mediates heterotypic cell-
cell adhesion between breast cancer epithelial cells and fibroblasts.
PLoS One. 2012;7:e33289.
57. Kaessmeyer S, Bhoola K, Baltic S, Thompson P, Plendl J. Lung
cancer neovascularisation: cellular and molecular interaction
between endothelial and lung cancer cells. Immunobiology.
2014;219:308-314.
58. Delgado-Bellido D, Serrano-Saenz S, Fernández-Cortés M, Oliver
FJ. Vasculogenic mimicry signaling revisited: focus on non-vascular
VE-c adherin. Mol Cancer. 2017;16:65.
59. Villanelo F, Escalona Y, Pareja-Barrueto C, Garate JA, Skerrett IM,
Perez-Acle T. Accessing gap-junction channel structure-function
relationships through molecular modeling and simulations. BMC Cell
Biol. 2017;18:5.
60. Aasen T, Leithe E, Graham SV, et al. Connexins in cancer: bridging
the gap to the clinic. Oncogene. 2019;38:4429-4 451.
61. Saccheri F, Pozzi C, Avogadri F, et al. Bacteria-induced gap junctions
in tumors favor antigen cross-presentation and antitumor immunity. Sci Transl Med. 2010;2:44ra57.
62. Aucher A, Rudnicka D, Davis DM. MicroRNAs transfer from human
macrophages to hepato-c arcinoma cells and inhibit proliferation. J
Immunol. 2013;191:6250-6260.
63. Wang WK, Chen MC, Leong HF, Kuo YL, Kuo CY, Lee CH. Connexin
43 suppresses tumor angiogenesis by down-regulation of vascular
endothelial growth factor via hypoxic-induced factor-1α. Int J Mol
Sci. 2014;16:439-451.
6 4. Karpinich NO, Caron KM. Gap junction coupling is required for
tumor cell migration through lymphatic endothelium. Arterioscler
Thromb Vasc Biol. 2015;35:1147-1155.
65. Sin WC, Aftab Q, Bechberger JF, Leung JH, Chen H, Naus CC.
Astrocytes promote glioma invasion via the gap junction protein
connexin43. Oncogene. 2016;35:1504-1516.
SATO et al
66. Chen Q, Boire A, Jin X, et al. Carcinoma-astrocyte gap junctions promote brain metastasis by cGAMP transfer. Nature.
2016;533:493-498.
67. Pasquale EB. Eph-ephrin bidirectional signaling in physiology and
disease. Cell. 2008;133:38-52.
68. Cortina C, Palomo-Ponce S, Iglesias M, et al. EphB-ephrin-B interactions suppress colorectal cancer progression by compartmentalizing tumor cells. Nat Genet. 2007;39:1376-1383.
69. Guo H, Miao H, Gerber L, et al. Disruption of EphA2 receptor tyrosine kinase leads to increased susceptibility to carcinogenesis in
mouse skin. Cancer Res. 2006;66:7050-7058.
70. Pasquale EB. Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Nat Rev Cancer. 2010;10:165-180.
71. Lu H, Clauser KR, Tam WL, et al. A breast cancer stem cell niche
supported by juxtacrine signalling from monocytes and macrophages. Nat Cell Biol. 2014;16:1105-1117.
72. Meurette O, Mehlen P. Notch signaling in the tumor microenvironment. Cancer Cell. 2018;34:536-548.
73. Sonoshita M, Aoki M, Fuwa H, et al. Suppression of colon cancer
metastasis by Aes through inhibition of Notch signaling. Cancer Cell.
2011;19:125-137.
74. Zhu TS, Costello MA, Talsma CE, et al. Endothelial cells create a
stem cell niche in glioblastoma by providing NOTCH ligands
that nurture self-
renewal of cancer stem-
like cells. Cancer Res.
2011;71:6061-6072.
75. Boelens MC, Wu TJ, Nabet BY, et al. Exosome transfer from stromal
to breast cancer cells regulates therapy resistance pathways. Cell.
2014;159:499-513.
76. Choi JH, Park JT, Davidson B, Morin PJ, Shih IM, Wang TL. Jagged-1
and Notch3 juxtacrine loop regulates ovarian tumor growth and adhesion. Cancer Res. 2008;68:5716-5723.
77. Han Y, Liu D, Li L. PD-1/PD-L1 pathway: current researches in cancer. Am J Cancer Res. 2020;10:727-742.
78. Liu S, Chen S, Yuan W, Wang H, Chen K, Li D. PD-1/PD-L1 interaction up-
regulates MDR1/P-
gp expression in breast cancer cells via PI3K/AKT and MAPK/ERK pathways. Oncotarget.
2017;8:99901-99912.
79. Roehlecke C, Schmidt MHH. Tunneling nanotubes and tumor microtubes in cancer. Cancers (Basel). 2020;12:857.
8 0. Hase K, Kimura S, Takatsu H, et al. M-Sec promotes membrane
nanotube formation by interacting with Ral and the exocyst complex. Nat Cell Biol. 2009;11:1427-1432.
81. Hanna SJ, McCoy-S imandle K, Leung E, Genna A, Condeelis
J, Cox D. Tunneling nanotubes, a novel mode of tumor cell-
macrophage communication in tumor cell invasion. J Cell Sci.
2019;132:jcs223321.
82. Osswald M, Jung E, Sahm F, et al. Brain tumour cells interconnect to
a functional and resistant network. Nature. 2015;528:93-98.
83. Sawanyawisuth K, Tantapotinan N, Wongkham C, et al. Suppression
of trophoblast cell surface antigen 2 enhances proliferation and migration in liver fluke-associated cholangiocarcinoma. Ann Hepatol.
2016;15:71-81.
8 4. Bowler MA, Bersi MR, Ryzhova LM, Jerrell RJ, Parekh A, Merryman
WD. Cadherin-11 as a regulator of valve myofibroblast mechanobiology. Am J Physiol Heart Circ Physiol. 2018;315:H1614-H1626.
How to cite this article: Sato A, Rahman NIA, Shimizu A,
Ogita H. Cell-to-cell contact-mediated regulation of tumor
behavior in the tumor microenvironment. Cancer Sci.
2021;00:1–8. https://doi.org/10.1111/cas.15114
...
論文の公開元へ
